Title:
HUMAN PAPILLOMAVIRUS-SPECIFIC T CELL RECEPTOR, CELL EXPRESSING SAME, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/060948
Kind Code:
A1
Abstract:
The present invention relates to a T cell receptor (TCR) specifically binding to a human papillomavirus E7, a nucleic acid encoding the TCR, an engineered cell comprising same, and a method for preparing the engineered cell. The present invention further relates to a fusion protein or a conjugate comprising the TCR, a method for editing genomes of a human cell, and a composition for editing the genomes of the human cell. Provided are a method for selectively amplifying the engineered cell and use of the TCR and the engineered cell in preventing and/or treating human papillomavirus infection.
Inventors:
PENG SONGMING (CN)
AN DUO (CN)
ZHONG SHAN (CN)
CHANG SHIWEI (CN)
AN DUO (CN)
ZHONG SHAN (CN)
CHANG SHIWEI (CN)
Application Number:
PCT/CN2023/115771
Publication Date:
March 28, 2024
Filing Date:
August 30, 2023
Export Citation:
Assignee:
NEOWISE BIOTECHNOLOGY CO LTD (CN)
International Classes:
C07K14/725; A61K39/00; A61P15/00; A61P31/20; A61P35/00; C07K19/00; C12N15/10; C12N15/113; C12N15/12; C12N15/85
Foreign References:
| CN106661098A | 2017-05-10 | |||
| CN110357952A | 2019-10-22 | |||
| CN112480239A | 2021-03-12 |
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF: